Cerenia 16 mg Tablets for Dogs

Vomiting can be associated with serious, severely debilitating conditions including
gastrointestinal obstructions; therefore, appropriate diagnostic evaluations should be
employed.

Revised: February 2024
AN: 02653/2022
Cerenia tablets have been shown to be effective in the treatment of emesis, however
where the frequency of vomiting is high, orally administered Cerenia may not be
absorbed before the next vomiting event occurs. It is therefore recommended to
initiate the treatment of emesis with Cerenia solution for injection.
Good veterinary practice indicates that antiemetics should be used in conjunction
with other veterinary and supportive measures, such as dietary control and fluid
replacement therapy while addressing the underlying causes of the vomiting. The
safety of maropitant during treatment beyond 5 days has not been explored in the
target population (i.e. young dogs suffering from viral enteritis). In case treatment for
a longer period than 5 days is regarded as necessary, careful monitoring of potential
adverse events should be implemented.

Special precautions for use in animals
The safety of the veterinary medicinal product has not been established in dogs less
than 16 weeks of age for the 8 mg/kg dose (motion sickness), and in dogs less than
8 weeks of age for the 2 mg/kg dose (vomiting) as well as in pregnant or lactating
bitches. Use only according to the benefit-risk assessment by the responsible
veterinarian.
Maropitant is metabolised in the liver and therefore should be used with caution in
patients with hepatic disease. As maropitant is accumulated in the body during a 14-
day treatment period due to metabolic saturation, careful monitoring of liver function
in addition to any adverse events should be implemented during long term treatment.
Cerenia should be used with caution in animals suffering from or with predisposition
for cardiac diseases as maropitant has affinity to Ca- and K-ion channels. Increases
of approximately 10% in the QT interval of the ECG were observed in a study on
healthy beagle dogs administered 8 mg/kg orally; however, such an increase is
unlikely to be of clinical significance.
Special precautions to be taken by the person administering the veterinary medicinal
product to animals
People with known hypersensitivity to maropitant should administer the veterinary
medicinal product with caution.
Wash hands after use. In case of accidental ingestion seek medical advice
immediately and show the package leaflet or the label to the physician.
Special precautions for the protection of the environment:
Not applicable.

Revised: February 2024
AN: 02653/2022